FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.
Key Details
- 1UltraSight's AI Echo Stewardship Platform now cleared by FDA for broader ultrasound compatibility.
- 2No new ultrasound equipment is required—compatible with handheld, laptop, and cart-based devices.
- 3Platform provides real-time, AI-assisted guidance for focused cardiac ultrasound (FoCUS) image acquisition.
- 4Aims to reduce variability and improve the usability of cardiac ultrasound by non-sonographer clinicians.
- 5Supports healthcare systems in scaling FoCUS exams without purchasing new hardware.
Why It Matters
By enabling AI-guided echocardiography on existing devices, this clearance lowers adoption barriers, expands cardiac imaging capabilities system-wide, and supports quality imaging by non-experts—potentially easing staff shortages and improving patient care accessibility.
Source
Cardiovascular Business
Related News
•Radiology Business
Radiology Dominates FDA AI Algorithm Clearances in 2026
Radiology accounted for 68 new FDA-cleared AI algorithms in early 2026, making up more than three-quarters of all AI clinical clearances.
•Cardiovascular Business
Radiology Maintains Lead in FDA-Cleared AI Algorithms, Cardiology Follows
Radiology remains the top specialty for FDA-cleared AI, with cardiology as a strong second, particularly in cardiovascular imaging.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.